The risk of venous thromboembolism (VTE), or blood clots, in individuals with sickle cell trait (SCT) is higher than in individuals without the trait. However, the risk is lower than for those with ...
Mitapivat, the company’s lead PK activator, was previously granted FDA orphan drug designation for the treatment of PK deficiency, thalassemia, and sickle cell disease. Tebapivat is not approved for ...
Intelligent Alpha founder and CEO Doug Clinton joins the show to break down the investment ... a cell therapy treatment for sickle cell disease and beta-thalassemia. Seigerman notes that the uptake ...
Intelligent Alpha founder and CEO Doug Clinton joins the show to break down the investment ... a cell therapy treatment for sickle cell disease and beta-thalassemia. Seigerman notes that the uptake ...